Skip to main content
Clinical Trials/CTRI/2011/11/002138
CTRI/2011/11/002138
Recruiting
Phase 4

A Pilot Study To Evaluate The Effect Of N-Acetyl Cysteine (NAC) On The Bronchodilator Response With Inhaled Salbutamol And Ipratropium In Patients With Chronic Obstructive Pulmonary Disease (COPD)

Cipla Ltd0 sites30 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Chronic Obstructive Pulmonary Disease
Sponsor
Cipla Ltd
Enrollment
30
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Cipla Ltd

Eligibility Criteria

Inclusion Criteria

  • Adult males or females with a diagnosis of Chronic Obstructive Pulmonary Disease
  • COPD defined as FEV1/FVC \< 0\.7 and FEV1 \< 80% predicted

Exclusion Criteria

  • Previous history of diagnosis of asthma
  • Previous history of atopy except controlled allergic rhinitis
  • History of concomitant pulmonary disease
  • Patients with bronchogenic carcinoma
  • Patients having known hypersensitivity to NAC
  • Patients with peripheral eosinophill count more than 600/µl of blood.
  • Patients already on NAC therapy or any mucolytic agent
  • Patients having history suggestive of high antioxidant intake through nutritional route
  • COPD with exacerbation within the previous three months requiring oral steroids, nebulised bronchodilator, antibiotics or an emergency visit to the doctor
  • Patients having uncontrolled allergic rhinitis

Outcomes

Primary Outcomes

Not specified

Similar Trials